Spinal opioid receptors and adenosine release: neurochemical and behavioral characterization of opioid subtypes

• Published in: The Journal of pharmacology and experimental therapeutics Vol. 275; no. 1; pp. 84 - 93
• Main Authors: Cahill, C M, White, T D, Sawynok, J
• Format: Journal Article
• Language: English
• Published: United States American Society for Pharmacology and Experimental Therapeutics 01.10.1995
• Subjects: Adenosine - secretion; Analgesics - pharmacology; Animals; Behavior, Animal - drug effects; Behavior, Animal - physiology; Caffeine - pharmacology; Calcium - physiology; Enkephalin, D-Penicillamine (2,5); Enkephalins - pharmacology; Male; Nociceptors - drug effects; Nociceptors - physiology; Oligopeptides - pharmacology; Purinergic P1 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid - classification; Receptors, Opioid - drug effects; Receptors, Opioid - physiology; Receptors, Opioid, delta - agonists; Receptors, Opioid, kappa - antagonists & inhibitors; Receptors, Opioid, mu - agonists; Spinal Cord - secretion; Spinal Cord - ultrastructure; Synaptosomes - drug effects; Synaptosomes - secretion
• ISSN: 0022-3565; 1521-0103

Release of adenosine from the spinal cord contributes to spinal antinociception by morphine. Morphine induces a Ca(++)-dependent release of adenosine from dorsal spinal cord synaptosomes, which is augmented under partially depolarizing conditions. The present study examined the opioid receptor subtypes involved in this release, and determined whether adenosine is an important mediator of antinociception induced by the spinal administration of selective opioid agonists in rats. Nanomolar and micromolar concentrations of the selective mu opioid agonists DAMGO ([D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin) and PLO17 ([N-MePhe3,D-Pro4]morphiceptin) induced release of adenosine in a biphasic manner in the presence of a partial depolarization (addition of 6 mM K+ to the Krebs' medium). The delta opioid agonists DPDPE ([D-Pen2,D-Pen5]enkephalin) and DELT ([D-Ala2,Cys4]deltorphin) and the kappa opioid agonist U50488H (trans-(+/-)-3,4-dichloro-N-methyl-N-(2-(1-pyrroli-zemeacetamid e) had little effect on the release of adenosine except at high micromolar concentrations. Release of adenosine by mu (nanomolar) and delta (micromolar) ligands is Ca(++)-dependent, whereas the kappa (micromolar) receptor ligand releases adenosine via a Ca(++)-independent mechanism. Behavioral antinociception using the hot-plate threshold test revealed that intrathecal administration of the mu and delta opioid receptor agonists produced dose-dependent antinociception with an order of potency of DAMGO, PLO17 > morphine, DELT > DPDPE. An ED75 dose of morphine, DAMGO or PLO17 was attenuated dose-dependently by intrathecal pretreatment with the adenosine receptor antagonist caffeine. Caffeine did not block the antinociceptive response to delta agonists, but in fact augmented antinociception when combined with DPDPE and DELT. This augmentation was dose-dependent. This study demonstrates that activation of the mu receptor subtype is responsible for the opioid-induced release of adenosine from the spinal cord, that such release contributes to the spinal antinociception by mu agonists and that only release evoked by low doses of opioids is behaviorally relevant.